Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.37 |
| ▸ | GPR183 | P32249 | 1/20 | 0.37 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.34 |
| ▸ | MLNR | O43193 | 2/20 | 0.32 |
| ▸ | EED | O75530 | 1/20 | 0.32 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.31 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.31 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.31 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.31 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2895563 | 0.91 | GPR119 (0.38) | MAPTGPR119GPR183 | |
| SCHEMBL2888289 | 0.91 | GPR119 (0.38) | MAPTGPR119GPR183GSTP1 | |
| SCHEMBL2894063 | 0.90 | GPR119 (0.37) | MAPTGPR119GPR183 | |
| SCHEMBL3663119 | 0.89 | GPR119 (0.37) | MAPTGPR119GPR183TP53 | |
| SCHEMBL2891418 | 0.88 | GPR119 (0.38) | MAPTGPR119GPR183 | |
| SCHEMBL13024332 | 0.88 | GPR119 (0.36) | MAPTGPR119GPR183 | |
| SCHEMBL2891413 | 0.88 | GPR119 (0.37) | GPR119GPR183 | |
| SCHEMBL2895880 | 0.87 | GPR119 (0.35) | MAPTGPR119GPR183TP53 | |
| SCHEMBL2895884 | 0.87 | GPR119 (0.35) | MAPTGPR119GPR183TP53 | |
| SCHEMBL2906289 | 0.87 | HDAC4 (0.37) | GPR119GPR183 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100286110-A1 | AZETIDINYL G-PROTEIN COUPLED RECEPTOR AGONISTS | PROSIDION LIMITED (GB) | 2010-11-11 | — | — | US | disclosed |
| US-20100286110-A1 | AZETIDINYL G-PROTEIN COUPLED RECEPTOR AGONISTS | PROSIDION LIMITED (GB) | 2010-11-11 | — | — | US | disclosed |
| US-20100286110-A1 | AZETIDINYL G-PROTEIN COUPLED RECEPTOR AGONISTS | PROSIDION LIMITED (GB) | 2010-11-11 | — | — | US | disclosed |
| WO-2009050523-A1 | AZETIDINYL G-PROTEIN COUPLED RECEPTOR AGONISTS | PROSIDION LIMITED (GB) | 2009-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286110-A1 | AZETIDINYL G-PROTEIN COUPLED RECEPTOR AGONISTS | GPR119, GIPR, GPR39 | MAPT 4834/4885GPR119 1/4885GPR183 30/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.